ST.
PETERSBURG, Fla., June 30,
2022 /PRNewswire/ -- Isleworth Healthcare Acquisition
Corporation (Nasdaq: ISLE)("Isleworth"), a special purpose
acquisition company, today announced that it has entered into an
agreement with Cytovia Holdings, Inc. ("Cytovia"), a
biopharmaceutical company empowering natural killer (NK) cells to
fight cancer through stem cell engineering and multispecific
antibodies (the "Termination Agreement") to terminate its
previously announced Merger Agreement with Cytovia, which was
executed in April 2022. The
Termination Agreement is effective immediately, and contains mutual
releases and covenants not to sue.
A copy of the Termination Agreement is filed as an exhibit to a
Current Report on Form 8-K filed by Isleworth today.
About Isleworth Healthcare
Acquisition Corp.
Isleworth Healthcare Acquisition Corp. is a blank check company
organized for the purpose of effecting a merger, share exchange,
asset acquisition, stock purchase, recapitalization,
reorganization, or other similar business combination with one or
more businesses or entities. We have operating expertise in
managing large and high growth businesses and more specifically, in
the life sciences industry. Collectively, we have built, managed,
bought and sold companies or technologies all over the world.
The team includes Al Weiss
(Chairman, Director), former President, Worldwide Operations
Walt Disney Parks and Resorts;
Bob Whitehead (CEO, Director), a
long-standing pharmaceutical executive, in the United States and internationally, and in
large and emerging stage companies; Dan
Halvorson (EVP & CFO, Director), experienced public and
private company executive in financial planning and operations in
the life science, technology and artificial intelligence
industries; Vipul Patel, MD,
(Director), a pioneer in the development and utilization of robotic
surgical technologies, and is connected to many emerging stage med
tech and device companies; Monica
Reed, M.D. (Director), an experienced healthcare leader of
large regional healthcare systems and community hospitals, and
serves on various bioscience boards; Bob
Dahl (Director), formerly Managing Director of Healthcare
Investments at the Carlyle Group and was previously co-head of
healthcare investment banking at Credit Suisse; and Michelle McKenna (Director), an experienced
board member and she has significant experience in M&A and
early stage companies, and as a C-suite executive of the NFL, she
was responsible for the highly effective Covid-19 contract tracing
program across the league.
Forward-Looking
Statements
Certain statements included in this press release that are not
historical facts are forward-looking statements for purposes of the
safe harbor provisions under the United States Private Securities
Litigation Reform Act of 1995. Forward-looking statements generally
are accompanied by words such as "believe," "may," "will,
"estimate," "continue," anticipate," "intend," expect,"
"should," "would," "plan," "predict," "potential," "seem," "seek,"
"future," "outlook," and similar expressions that predict or
indicate future events or trends or that are not statements of
historical matters. These statements are based on various
assumptions, whether or not identified in this press release, and
on the current expectations of management and are not predictions
of actual performance. These forward-looking statements are not
intended to serve as, and must not be relied on by an investor as,
a guarantee, an assurance, a prediction, or a definitive
statement of fact or probability. Actual events and circumstances
are difficult or impossible to predict and will differ from
assumptions this press release relies on. Many actual events and
circumstances are beyond the control of Isleworth. These
forward-looking statements are subject to a number of risks and
uncertainties including (i) any changes to accounting methods of
Isleworth; (ii) the risk factors included in this press release;
and (iii) those factors discussed in Isleworth's Annual Report on
Form 10-K for the year ended December 31,
2021, and on its Quarterly Report on Form 10-Q for the
period ended March 31, 2022, under
the heading "Risk Factors," and other documents Isleworth has
filed, or will file, with the Securities and Exchange Commission
(the "SEC"). If any of these risks materialize or our assumptions
prove incorrect, actual results could differ materially from the
results implied by these forward-looking statements.
Isleworth Healthcare Acquisition Corp.
Contact:
Dan Halvorson
EVP & CFO, Director
dan@isleworthhealthcare.com
View original
content:https://www.prnewswire.com/news-releases/isleworth-and-cytovia-terminate-merger-agreement-301579200.html
SOURCE Isleworth Healthcare Acquisition Corp.
